NCT00920556 - A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2009

Primary Completion Date

November 4, 2010

Study Completion Date

November 4, 2010

Conditions

Multiple Myeloma

Interventions

DRUG

5.0g SRT501

5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.

DRUG

Bortezomib

Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.

Trial Locations (5)

7100

GSK Investigational Site, Vejle

SM2 5NG

GSK Investigational Site, Sutton

B15 2TH

GSK Investigational Site, Birmingham

LS9 7TF

GSK Investigational Site, Leeds

EC1A 7BE

GSK Investigational Site, London